GEN Exclusives

More »

GEN News Highlights

More »
Jun 18, 2007

Novartis Inks Pact with Adenosine Therapeutics to Develop Drugs for Diabetes and Asthma

  • Novartis acquired an option to Adenosine Therapeutics’ (ATL) A2B receptor antagonist program. Adenosine Therapeutics will continue to develop the program for the oral treatment of type 2 diabetes, asthma, and other disorders.

    "Collaborating with Novartis allows Adenosine Therapeutics to complement its internal research capabilities with those of this well-respected leader in the pharmaceutical industry and provides robust financing to take the program forward into clinical development,” points out Robert S. Capon, CEO and co-founder of Adenosine Therapeutics.

    In addition to the drug candidates developed by ATL, Novartis obtained an exclusive option to the U.S. patent that covers the use of A2B receptor antagonists for the treatment of diabetes and related diseases.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

New Drugs for Ebola

Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?